Updates in chemoprevention research for hereditary gastrointestinal and polyposis syndromes.

ABSTRACT:

Purpose of review

To critically examine recently published research in the area of chemoprevention in hereditary polyposis and gastrointestinal cancers, and to briefly review several ongoing chemoprevention trials testing novel agents in this population.

Recent findings

Four recent chemoprevention trials in patients with familial adenomatous polyposis (FAP) were identified and reviewed. In the FAPEST trial, the combination of erlotinib+sulindac (compared to placebo) met its primary outcome of decreased duodenal polyp burden. A secondary analysis of lower gastrointestinal tract outcomes also demonstrated significant benefits. Two randomized trials in FAP patients examining combination regimens (celecoxib+DFMO and sulindac+DFMO) failed to meet their primary endpoints. Benefits

SUBMITTER: Hall MJ 

PROVIDER: S-EPMC8240460 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature